Half-life is one of the most important pharmacokinetic concepts in peptide research, yet it is frequently misunderstood or oversimplified. Understanding how half-life affects peptide behaviour in biological systems is essential for designing meaningful research protocols, interpreting published studies, and understanding why some peptides require frequent administration while others remain active for days or weeks.
This guide provides a thorough introduction to peptide half-life — the science behind it, how it varies across commonly researched peptide classes, and what it means for experimental design.
What Is Half-Life?
Half-life (t½) is the time required for the concentration of a substance in a biological system to fall to 50% of its initial value. It is a key pharmacokinetic parameter that describes the rate at which a drug or compound is eliminated from the body through metabolism, excretion, or both.
For peptides specifically, half-life is primarily determined by enzymatic degradation — proteases in the bloodstream and tissues cleave peptide bonds, breaking the molecule into smaller fragments that are typically inactive and subsequently cleared by the kidneys or liver. The faster this degradation occurs, the shorter the half-life.
Half-life is mathematically related to the elimination rate constant (k): t½ = 0.693/k. For compounds following first-order kinetics (where elimination rate is proportional to concentration), the half-life is constant regardless of initial dose — meaning that after one half-life, 50% remains; after two, 25%; after three, 12.5%; after approximately seven half-lives, less than 1% of the original concentration remains.
Why Do Peptides Generally Have Short Half-Lives?
Peptides face a hostile pharmacokinetic environment in biological systems. Several factors contribute to their typically short half-lives:
Proteolytic enzymes: Serum proteases, peptidases in the kidneys (particularly prolyl endopeptidase and dipeptidyl peptidase IV/DPP-IV), and tissue-based enzymes collectively create a highly active degradation environment for peptide sequences. Any unmodified linear peptide is susceptible to rapid cleavage at vulnerable bond positions.
Renal clearance: Small peptides (below approximately 5-8 kDa) are filtered by the kidney glomerulus and can be excreted intact or further degraded by tubular peptidases. This limits the circulating lifespan of smaller peptide compounds.
Hepatic metabolism: The liver contains extensive peptidase activity and processes a significant fraction of circulating peptides during first-pass circulation (for orally administered compounds) and general hepatic blood flow.
No protein binding protection: Unlike many small-molecule drugs that bind to plasma proteins (particularly albumin), creating a “reservoir” that slows elimination, most peptides have limited plasma protein binding and thus circulate freely and are rapidly accessible to degradation enzymes.
Half-Lives of Commonly Researched Peptides
Half-life varies enormously across different peptide classes. The following figures represent published or commonly cited research estimates — actual values can vary with route of administration, species, and experimental conditions:
Growth Hormone Releasing Peptides (GHRPs)
GHRP-6: Plasma half-life approximately 15–60 minutes following subcutaneous administration. Peak GH stimulation occurs within 15-30 minutes of administration. Requires multiple daily administrations to maintain sustained GH secretion in research protocols.
GHRP-2: Similar to GHRP-6, approximately 30 minutes. More potent GH stimulator per unit but similar kinetic profile.
Ipamorelin: Half-life approximately 2 hours. Slightly longer than GHRP-6/GHRP-2, contributing to its lower side effect profile (reduced cortisol and prolactin spillover from briefer peak GH pulses with GHRP-6 being less relevant with ipamorelin’s more selective profile).
Hexarelin: Half-life approximately 1-2 hours. Among the most potent GHRP-class compounds. Prolonged use leads to desensitisation due to short but intense GH pulses.
Growth Hormone Releasing Hormones (GHRHs)
Sermorelin: Very short half-life of approximately 10-20 minutes. Closely mimics the structure of endogenous GHRH(1-44) and shares its rapid clearance. Typically administered multiple times daily or via subcutaneous injection immediately before sleep to mimic physiological GH pulse.
CJC-1295 (without DAC): Half-life approximately 30 minutes. Structurally modified GHRH analogue. Combines well with GHRPs for synergistic GH release due to complementary mechanisms.
CJC-1295 with DAC (Drug Affinity Complex): Half-life dramatically extended to approximately 8 days by the addition of a Drug Affinity Complex that binds to albumin. This albumin binding acts as a slow-release reservoir, providing sustained GHRH activity over 1-2 weeks per injection. Fundamentally changes the pharmacokinetic profile and therefore the research paradigm.
Tesamorelin: Half-life approximately 26-38 minutes. A stabilised GHRH analogue approved for HIV-associated lipodystrophy. More resistant to dipeptidyl peptidase degradation than native GHRH.
Tissue Repair Peptides
BPC-157: Half-life not definitively established in human pharmacokinetics; animal studies suggest rapid clearance (minutes to low hours) following systemic administration, but tissue effects persist substantially longer than circulating half-life suggests — possibly due to receptor upregulation or downstream signalling cascade activation.
TB-500 (Thymosin Beta-4 fragment): Thymosin Beta-4 has a plasma half-life of approximately 30 minutes, though TB-500 (the 4-amino acid sequence Ac-SDKP) has different characteristics. Tissue retention appears to exceed plasma half-life significantly.
Melanocortin Peptides
Melanotan 2: Half-life approximately 30 minutes to 1 hour following subcutaneous injection. Despite short half-life, pigmentation effects (via melanin synthesis) persist for days to weeks as melanocytes have been stimulated to produce melanin.
PT-141 (Bremelanotide): Half-life approximately 1-2 hours. Approved as Vyleesi for hypoactive sexual desire disorder. Short half-life aligns with its use as an acute-administration compound rather than chronic therapy.
Cognitive and Nootropic Peptides
Semax: Half-life approximately 1-2 minutes in plasma when administered intranasally, though CNS effects persist far longer (hours) due to rapid blood-brain barrier penetration and receptor engagement before enzymatic clearance.
Selank: Half-life approximately 3-5 minutes in plasma; again, CNS effects outlast circulating levels significantly due to rapid central distribution.
Dihexa (research stage): Estimated half-life of several hours; notably lipophilic compared to most peptides, improving CNS penetration and duration.
Copper Peptides
GHK-Cu: The endogenous tripeptide GHK-Cu has a short plasma half-life. Exogenous GHK-Cu administered topically bypasses systemic pharmacokinetics almost entirely — local dermal tissue concentration and duration of action depend on formulation rather than plasma half-life.
How Half-Life Affects Research Protocol Design
Half-life is not merely academic — it directly determines how research protocols should be structured:
Dosing frequency: Compounds with short half-lives require more frequent administration to maintain therapeutic concentrations above the minimum effective threshold. GHRP-6 with its ~30-minute half-life is typically administered 2-3 times daily in GH research protocols. CJC-1295 DAC with its 8-day half-life can be administered weekly or bi-weekly.
Peak vs. trough strategy: Some research applications specifically exploit short half-lives to produce pulsatile effects mimicking physiological patterns (e.g., GH is secreted in pulses, not continuously). In these cases, a short-half-life compound may be preferable to a long-acting analogue specifically because it creates discrete peaks rather than continuous elevation.
Tissue vs. plasma half-life discordance: Many peptides show longer effects than plasma half-life predicts because they activate signalling cascades, upregulate receptors, or stimulate protein synthesis that continues after the peptide is cleared. BPC-157 is a notable example — its tissue repair effects substantially outlast its circulating presence.
Accumulation with repeated dosing: For compounds with longer half-lives, repeated dosing leads to accumulation. With CJC-1295 DAC, for example, weekly administration gradually builds plasma GHRH activity over several weeks before reaching steady state. Researchers must account for this accumulation in study design.
Strategies Used to Extend Peptide Half-Life
Pharmaceutical and research peptide development has produced several strategies for extending the typically short half-lives of natural peptides:
PEGylation: Attachment of polyethylene glycol (PEG) chains to the peptide significantly increases molecular size, reducing renal filtration, and sterically shields peptide bonds from protease access. PEG-MGF (mechano growth factor) is an example of PEGylation extending a short-lived peptide.
Albumin binding (Drug Affinity Complex): As in CJC-1295 DAC, linking a compound to an albumin-binding moiety exploits albumin’s long half-life (~19 days) as a slow-release reservoir.
D-amino acid substitution: Natural peptides use L-amino acids. Substituting D-amino acid enantiomers at cleavage-vulnerable positions confers protease resistance. Many advanced research peptides incorporate D-amino acids for this purpose.
Cyclisation: Forming cyclic peptide structures (head-to-tail or via side-chain bonds) reduces the conformational flexibility that proteases require to access and cleave bonds.
Lipidation: Attaching fatty acid chains (as in semaglutide and liraglutide) promotes albumin binding and subcutaneous depot formation, dramatically extending effective half-life of GLP-1 analogues from minutes (native GLP-1) to hours or days.
Route of Administration and Half-Life
The route of administration significantly affects effective half-life and bioavailability:
Subcutaneous injection: Creates a local depot from which the compound diffuses into circulation gradually, producing a more extended absorption phase and effectively smoothing out peak concentrations compared to intravenous delivery.
Intramuscular injection: Faster absorption than subcutaneous for most peptides, producing higher early peaks but similar overall half-life once in circulation.
Intranasal: For CNS-targeting peptides (Semax, Selank), intranasal delivery exploits the olfactory nerve pathway for rapid direct CNS access, bypassing blood-brain barrier and systemic circulation largely — making plasma half-life almost irrelevant to CNS effects.
Oral: Most peptides are poorly bioavailable orally due to acid hydrolysis in the stomach and enzymatic degradation in the intestine. Collagen peptides are an exception — their small size and specific di/tripeptide sequences allow partial absorption. Most research peptides are not suitable for oral administration.
Practical Implications for UK Researchers
For researchers in the UK working with peptide compounds, understanding half-life has direct implications for study design:
Blood sampling timing must account for compound half-life — sampling too late will miss peak concentrations; sampling too early relative to the elimination profile will miss the trough and accumulation dynamics. Outcome measures should be aligned with the biological mechanism’s timeline, not just the pharmacokinetic half-life. Washout periods between experimental conditions should be at least 5-7 half-lives to ensure complete clearance (>97% elimination). Storage and reconstitution protocols affect compound stability, which functionally determines the “half-life” of peptide activity in solution — always store according to manufacturer specifications and use within recommended timeframes after reconstitution.
🔗 Related Reading: For our complete introductory guide covering how peptides work, classes, and UK research considerations, see our Research Peptides for Beginners: A Complete UK Introduction (2026).
Frequently Asked Questions
What is the half-life of BPC-157?
BPC-157 does not have a firmly established human pharmacokinetic half-life in published literature. Animal studies suggest rapid plasma clearance (potentially minutes to low hours), but tissue repair effects persist substantially longer — likely due to downstream cellular signalling rather than continued peptide presence.
Why does CJC-1295 with DAC last so much longer than without DAC?
The Drug Affinity Complex (DAC) modification adds a chemical group that binds to albumin, the most abundant plasma protein. Albumin has a half-life of approximately 19 days, effectively acting as a slow-release reservoir. Without DAC, CJC-1295 has a half-life of ~30 minutes; with DAC, it extends to approximately 8 days.
Does a shorter half-life mean a peptide is less effective?
Not necessarily. Effectiveness depends on mechanism, potency, and receptor engagement — not half-life alone. A short-acting peptide that strongly activates a cascade with persistent downstream effects (like BPC-157 or Semax) can have therapeutic duration far exceeding its pharmacokinetic half-life.
How does peptide half-life affect when to administer for best results?
Timing administration around specific physiological events (meals, sleep, training) is more relevant for short-half-life compounds. GHRP/GHRH combinations are often administered at night to amplify the natural GH pulse that occurs during slow-wave sleep. For long-half-life compounds like CJC-1295 DAC, timing relative to daily physiology becomes less critical.
🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified peptides for research and laboratory use. View UK stock →
